Company: KROS
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001664710-25-000046
Chunk: 121

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Item 1
Chunk 121
---
 three months ended March 31, 2025. The carrying values of other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. 

4. PREPAID EXPENSES AND OTHER CURRENT ASSETS 

Prepaid expenses and other current assets consisted of the following (in thousands): MARCH 31,2025DECEMBER 31,2024Prepaid external R&D costs$14,587 $15,748 Prepaid external manufacturing costs449 5,545 Prepaid sales tax275 121 Prepaid insurance210 651 Prepaid subscriptions1,134 960 Interest and dividend receivable2,083 1,714 Other2,939 1,481 Total prepaid expenses and other current assets$21,677 $26,220 

11

5. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES 

Accrued expenses and other current liabilities consisted of the following (in thousands): MARCH 31,2025DECEMBER 31,2024Accrued external R&D costs$6,605 $5,139 Accrued external manufacturing costs3,402 4,308 Accrued compensation and benefits5,292 10,130 Accrued legal and consulting fees1,459 877 Other532 416 Total accrued expenses and other current liabilities$17,290 $20,870 

Accrued compensation and benefits consisted primarily of accrued payroll and accrued vacation.

6. COMMON STOCK

As of March 31, 2025, the Company’s amended and restated certificate of incorporation authorized the Company to issue 200,000,000 shares of common stock at a par value of $0.0001 per share.

On January 8, 2024, the Company closed an underwritten public offering in which 4,025,000 shares of common stock were issued and sold, which included 525,000 shares of common stock issued and sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $40.00 per share. The aggregate net proceeds to the Company from the public offering were approximately $151.1 million, after deducting underwriting discount, commissions and offering expenses. 

7. STOCK-BASED COMPENSATION

2017 Stock Incentive PlanThe Board adopted the 2017 Stock Incentive Plan (the